澳门大阳城122.ccapp官方下载

目录产品 » 重组蛋白 » SARS-CoV-2 Spike protein (S1)
Manual
SDS
COAs

SARS-CoV-2 Spike protein (S1)

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. S protein plays an important role in the induction of neutralizing-antibodies and T-cell responses, as well as protective immunity.
￥3800
Z03501

产品简介
Species SARS-CoV-2
Protein Construction
S1 protein (Gln14-Arg685)
Accession # P0DTC2
Purity > 90% as analyzed by SDS-PAGE
Endotoxin Level < 0.2 EU/μg of protein by gel clotting method
Biological Activity SARS-CoV-2 Spike protein (S1) can bind with Human ACE2 in functional ELISA assay.
Expression System 293 Cells
Theoretical Molecular Weight 78.3 kDa
(Additional amino acids from the vector are included. The sequence of them is confidential.)
Formulation Supplied as a solution in PBS pH 7.4
Concentration Please refer to the COA for the specific lot.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at -20°C or below. Avoid repeated freeze-thaw cycles.
返回

图例
SARS-CoV-2 Spike Protein (S1)

»

SARS-CoV-2 Spike Protein (S1)

»

SARS-CoV-2 Spike Protein (S1)

Western blot analysis of SARS-CoV-2 Spike protein (S1) (GenScript, Z03501) using S1 Antibody(GenScript, A02053).
Lane 1: 10 ng of Z03501
Lane 2: 5ng of Z03501 »

SARS-CoV-2 Spike Protein (S1)

Immobilized SARS-CoV-2 Spike protein (S1) (Cat. No. Z03501) at 1 μg/mL can bind ACE-2 Fc Chimera, Human (Cat. No. Z03484) with a serial dilution.
Mouse Anti-Human IgG Fc Antibody[HRP], mAb (Cat.No. A01854) is used as a secondary antibody (0.1 μg/mL). »

SARS-CoV-2 Spike Protein (S1)

Lane 1: 2μg of SARS-CoV-2 Spike protein (S1), reducing(R)
Lane 2: 2μg of SARS-CoV-2 Spike protein (S1), non-reducing(NR)
> 85% as analyzed by SDS-PAGE »

<
>

技术背景
Target Background SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. S protein plays an important role in the induction of neutralizing-antibodies and T-cell responses, as well as protective immunity.
Synonyms SARS-CoV-2 S1 protein; 2019-nCoV S1 protein
返回

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


相关文献
Hongjie Wang, et al. In vivo HSC gene therapy for SARS-CoV2 infection using a decoy receptor. Hum Gene Ther. (2022-01)
Belén Aparicio, et al. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerg Microbes Infect. (2021-12)
Gang Zeng, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. (2021-12)
Krista G Freeman, et al. A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display. Microorganisms. (2021-11)
Yuta Kyosei, et al. Ultrasensitive Detection of SARS-CoV-2 Spike Proteins Using the Thio-NAD Cycling Reaction: A Preliminary Study before Clinical Trials. Microorganisms. (2021-10)
Hongguang Liang, et al. ARRB2 promotes colorectal cancer growth through triggering WTAP. Acta Biochim Biophys Sin (Shanghai). (2021-01)
W Dioh, et al. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Trials. (2021-01)
Hicks SM, et al. A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. The Journal of Infectious Diseases. (2021-01)
Julia A Zakashansky, et al. Detection of the SARS-CoV-2 spike protein in saliva with Shrinky-Dink© electrodes. medrxiv. (2020-11)
Zeng C, et al. Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo. Advanced materials (Deerfield Beach, Fla.). (2020-10)
Yuta Kyosei, et al. Proposal of De Novo Antigen Test for COVID-19: Ultrasensitive Detection of Spike Proteins of SARS-CoV-2. Diagnostics (Basel). (2020)
Kirill Gorshkov, et al. Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid. biorxiv. (2020)
查看更多
返回